Gilead Sciences develops and markets medicines for HIV, viral hepatitis, oncology, and other serious diseases. Its HIV portfolio includes established antiretroviral treatments and long-acting prevention approaches, while Kite provides cell therapies for selected blood cancers. The company also invests in oncology drug development and partnerships, generating most revenue from prescription medicines.
Gilead Sciences Inc. (GILD) has a MarketKingdoms composite score of 65.5 (B), an B-range rating. It ranks 768th of 1,866 covered companies, 33rd of 78 in Healthcare (sector average 64.4) and 6th of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are Stock selection at 82 (Healthcare average 79) and Industry opportunity at 81 (Healthcare average 81). Its weakest lenses are Expansion (growth) at 27 (sector average 50) and Price (valuation) at 39 (sector average 50).
| Lens | Type | GILD | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 82 | 79 | 78 | 69th |
| KPI momentum | Research signal | 81 | 78 | 77 | 56th |
| Catalyst watch | Research signal | 77 | 74 | 71 | 72nd |
| Price (valuation) | Fundamental lens | 39 | 50 | 53 | 33rd |
| Expansion (growth) | Fundamental lens | 27 | 50 | 39 | 14th |
| Quality (profitability) | Fundamental lens | 44 | 50 | 60 | 45th |
| Trend (momentum) | Fundamental lens | 68 | 50 | 55 | 72nd |
The most recent call analysed was held on 2026-08-04 (fiscal 2026 Q2). After it the composite moved from 81.7 to 81.0. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 65.5.
The stock's valuation gap is -3.5%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 1.08, sector beta 0.30, industry beta 0.68; the factor model explains 54% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Bristol-Myers Squibb Co. (BMY) | 66.3 | B | -11.0% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| GSK plc ADR (GSK) | 63.0 | B- | -5.1% |
| Novo Nordisk ADR (NVO) | 62.9 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
Gilead Sciences Inc. financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.